L'etude clinique du mois. L'etude ADOPT: quel antidiabetique oral initier chez le patient diabetique de type 2? ; ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?
peer reviewed ; ADOPT ("A Diabetes Outcome Progression Trial") is a double-blind, controlled clinical trial that aims at assessing the efficacy of rosiglitazone, as compared to metformin or glibenclamide, in maintaining long-term glycaemic control in patients with recently diagnosed type 2 diabetes. It randomized 4,360 patients who were followed for a median of 4.0 years. The cumulative incidence of monotherapy failure (defined as a confirmed level of fasting plasma glucose level of more than 180 mg/dl) averaged at 5 years 15% with rosiglitazone, 21% with metformin, and 34% with glibenclamide.... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | journal article |
Erscheinungsdatum: | 2007 |
Verlag/Hrsg.: |
Université de Liège. Revue Médicale de Liège
|
Schlagwörter: | Administration / Oral / Belgium / Canada / Cost-Benefit Analysis / Diabetes Mellitus / Type 2/drug therapy/economics / Double-Blind Method / European Union / Glyburide/therapeutic use / Humans / Hypoglycemic Agents/therapeutic use / Metformin/therapeutic use / Middle Aged / Quality of Life / Thiazolidinediones/therapeutic use / Treatment Outcome / United States / Human health sciences / Pharmacy / pharmacology & toxicology / Endocrinology / metabolism & nutrition / Sciences de la santé humaine / Pharmacie / pharmacologie & toxicologie / Endocrinologie / métabolisme & nutrition |
Sprache: | Französisch |
Permalink: | https://search.fid-benelux.de/Record/base-28535000 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://orbi.uliege.be/handle/2268/4095 |